Intermittent schedules of the oral RAF-MEK inhibitor CH5126766/VS-6766 in patients with RAS/RAF-mutant solid tumours and multiple myeloma: a single-centre, open-label, phase 1 dose-escalation and basket dose-expansion study.
- Submitting institution
-
Institute of Cancer Research: Royal Cancer Hospital (The)
- Unit of assessment
- 1 - Clinical Medicine
- Output identifier
- 207
- Type
- D - Journal article
- DOI
-
10.1016/S1470-2045(20)30464-2
- Title of journal
- Lancet Oncol
- Article number
- -
- First page
- 1478
- Volume
- 21
- Issue
- 11
- ISSN
- 1474-5488
- Open access status
- Compliant
- Month of publication
- November
- Year of publication
- 2020
- URL
-
-
- Supplementary information
-
https://www.sciencedirect.com/science/article/pii/S1470204520304642?via%3Dihub#sec1
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
25
- Research group(s)
-
-
- Citation count
- 2
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -
